Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Igc Pharma Inc (NY: IGC )

0.3525 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Igc Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
From IGC Pharma Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Interim Results from Phase 2 Study Evaluating Treatment to Reduce Alzheimer’s Agitation
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability... 
Via Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. 
Via Benzinga
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Benzinga Virtual Healthcare Summit 2024
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
From IGC Pharma, Inc.
Via Business Wire
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
From IGC Pharma, Inc.
Via Business Wire
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... 
Via Benzinga
IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
--News Direct-- 
Via News Direct
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Names Healthcare Leader to Board of Directors
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
From IGC Pharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports ‘Promising’ Results in Preclinical Studies Evaluating Drug Candidate for Alzheimer’s Treatment
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Spotlighted in Ascendiant Equity Analyst Report
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q3 2024 Financial Results, Reports Corporate Achievements
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
IGC Pharma Reports Third Quarter Fiscal 2024 Results
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data from Preclinical Studies Indicating Proprietary Drug Candidate Reduces Agitation in Alzheimer’s Mouse Model
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing Proprietary Drug Candidate TGR-63 Reduces Plaque in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Why IGC Pharma Stock Is Moving Higher
IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to... 
Via Benzinga
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Activates ClinCloud in Phase 2b Alzheimer’s Trial
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Milestone’ Patent for Drug Formulation Used to Treat Agitation in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Biotech Showcase and BioPartnering @ JPM
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
From IGC Pharma, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.